Brainmaxxing: what the evidence says about nootropics and focus stacks

Brainmaxxing — or focusmaxxing — is the effort to engineer sharper thinking, longer focus and better memory by stacking "nootropics", the loose category of supplements and drugs marketed as cognitive enhancers. A typical stack runs from the mundane (caffeine with L-theanine) through the herbal (lion's mane, bacopa) to the pharmaceutical (modafinil, prescribed for sleep disorders and taken off-label). The unifying promise is a measurable upgrade to a healthy brain. The evidence for that promise is strongest for the cheapest item on the list and gets thinner from there, and for the drug end it is thin in a way the marketing conceals.

This is standing informational reporting, not medical advice, and the prescription drugs discussed are used off-label for this purpose.

The one combination with real support

The best-evidenced stack is also the least exotic: caffeine paired with L-theanine, an amino acid found in tea. A controlled study of 27 healthy volunteers found that caffeine on its own improved subjective alertness and attention-switching accuracy, and that adding L-theanine improved both the speed and accuracy of attention-switching and reduced susceptibility to distraction [s1]. A systematic review and meta-analysis reached a consistent but modest verdict: moderate effect sizes favouring the combination for alertness and attention in the first couple of hours, with the caffeine dose appearing to do more of the work than the L-theanine [s2]. That is a real effect — small, short-lived, and mostly a smoother version of what caffeine already does.

Because caffeine is the active core, its dose and its ceiling matter, and our how much caffeine is too much piece and the coffee and cardiovascular risk meta-analysis cover both. The "stack" framing tends to obscure that most of the benefit is available from a cup of coffee.

The drug end: modafinil, off-label and overstated

Modafinil is the pharmaceutical the trend prizes, an approved wakefulness drug widely taken off-prescription for focus. A systematic review of its effects in healthy, non-sleep-deprived people found the picture genuinely mixed: on simple tasks, most studies showed improved executive function but only about half showed gains in attention or learning and memory — and a few reported impaired divergent, creative thinking [s3]. On more complex, demanding tasks the reviewers found more consistent enhancement of attention, executive function and learning, without a preponderance of side effects in the studies examined [s3]. That is a real but conditional signal, drawn from short-term laboratory testing, and it says nothing about the safety of taking a prescription drug regularly, without supervision, for a problem it was not prescribed to treat. "It works" and "it is a good idea" are different claims, and the trend collapses them.

Everything else, and the impairment catch

The rest of the stack — racetams, choline compounds, herbal extracts — is where the evidence thins to almost nothing for healthy users. A review of the nootropic landscape organises these into classical compounds, metabolism boosters, cholinergics and plant extracts, and its framing carries the key caveat: these substances improve thinking, learning and memory "especially in cases where these functions are impaired" [s4]. That qualifier is the whole game. Much of what evidence exists for nootropics comes from populations with cognitive impairment or decline, where a deficit can be partially corrected — not from healthy young people trying to exceed their baseline, where the ceiling effect leaves little to gain.

Racetams are the clearest case. Piracetam and its relatives are the original "classical" nootropics, and in the review's own framing their documented uses cluster around impaired cognition rather than enhancement of the healthy [s4]. They are not approved as cognitive enhancers, their side-effect and contraindication profiles are real, and the enthusiast literature promoting them for focus in healthy adults is not matched by controlled evidence [s4]. The same asymmetry runs through the herbal end of the stack: plausible mechanisms, small studies, soft endpoints, and effect sizes that shrink as the trials get more rigorous.

The same pattern shows up in adjacent optimisation claims. Brain-training games improve performance at the trained game and transfer poorly to general cognition, as our brain-training transfer trial piece sets out. Magnesium L-threonate, marketed for memory, rests on a single small trial, covered in our magnesium and cognition write-up. And supplement trials in general tend to report changes in biomarkers rather than outcomes anyone would notice, a recurring weakness our supplement biomarker-endpoints piece examines.

What to watch

Brainmaxxing's defensible core is one modest, well-tested combination that mostly amounts to caffeine used thoughtfully. Its overreach is treating a mixed, short-term drug literature and an essentially empty supplement literature as if they delivered the same reliable upgrade. The interventions with the best evidence for a healthy brain are the unglamorous ones the trend skips — sleep, exercise and managing stimulant intake — and no capsule stack has been shown to substitute for them.

Sources

• [s1] The combined effects of L-theanine and caffeine on cognitive performance and mood — Nutritional Neuroscience, 27 July 2008. https://doi.org/10.1179/147683008X301513
• [s2] Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis — Nutrition Reviews, 19 June 2014. https://doi.org/10.1111/nure.12120
• [s3] Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review — European Neuropsychopharmacology, 20 August 2015. https://doi.org/10.1016/j.euroneuro.2015.07.028
• [s4] Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs — Nutrients, 17 August 2022. https://doi.org/10.3390/nu14163367